Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

Clinical outcome of patients infected with hepatitis C virus infection on survival after primary liver transplantation under tacrolimus

Casavilla, EA and Rakela, J and Kapur, S and Irish, W and McMichael, J and Demetris, AJ and Starzl, TE and Fung, JJ (1998) Clinical outcome of patients infected with hepatitis C virus infection on survival after primary liver transplantation under tacrolimus. Liver Transplantation and Surgery, 4 (6). 448 - 454. ISSN 1074-3022

[img]
Preview
PDF
Accepted Version
Available under License : See the attached license file.

Download (899kB) | Preview
[img] Plain Text (licence)
Available under License : See the attached license file.

Download (1kB)

Abstract

The outcome of hepatitis C virus (HCV) infection on patient and graft survival after orthotopic liver transplantation (OLT) has been controversial. An earlier experience with a higher dose of tacrolimus (≥0.1 mg/kg/d intravenously and ≥0.2 mg/kg/d orally) was associated with a worse clinical outcome in patients infected with HCV. The clinical outcome of 183 liver transplant recipients with end-stage liver disease (ESLD) secondary to HCV infection (HCV group) was compared with a contemporary cohort of 556 patients with HCV infection who underwent transplantation for nonviral, nonmalignant ESLD (control group). All patients were prospectively screened for anti-HCV antibodies and HCV RNA by reverse-transcriptase polymerase chain reaction. All OLT patients were receiving low-dose tacrolimus immunosuppression. Cumulative patient survival rates for the HCV group were 80% after I year and 75% after 3 years compared with rates of 84% and 78%, respectively, in the control group (P = .452). Primary graft survival rates at the same time intervals for the HCV group and the control group were 72% and 77.5% at 1 year and 67% and 72% at 3 years, respectively (P = .144). The incidence of re-transplantation (re-OLT) in the HCV group and the control group was 12.6% and 10.4%, respectively (P = .42). Chronic HCV infection as an indication for OLT with a lower dose of tacrolimus immunosuppression (≤0.05 mg/kg/d intravenously and ≤0.1 mg/kg/d orally) is associated with a similar patient and graft survival as those without HCV infection.


Share

Citation/Export:
Social Networking:
Share |

Details

Item Type: Article
Status: Published
Creators/Authors:
CreatorsEmailPitt UsernameORCID
Casavilla, EA
Rakela, J
Kapur, S
Irish, W
McMichael, J
Demetris, AJ
Starzl, TEtes11@pitt.eduTES11
Fung, JJ
Centers: Other Centers, Institutes, or Units > Thomas E. Starzl Transplantation Institute
Date: 1 January 1998
Date Type: Publication
Journal or Publication Title: Liver Transplantation and Surgery
Volume: 4
Number: 6
Page Range: 448 - 454
DOI or Unique Handle: 10.1002/lt.500040605
Institution: University of Pittsburgh
Refereed: Yes
ISSN: 1074-3022
Other ID: uls-drl:31735062127778, Starzl CV No. 2056
Date Deposited: 08 Apr 2010 17:35
Last Modified: 27 Jan 2019 02:55
URI: http://d-scholarship.pitt.edu/id/eprint/5442

Metrics

Monthly Views for the past 3 years

Plum Analytics

Altmetric.com


Actions (login required)

View Item View Item